XB130 inhibits healing of diabetic skin ulcers through the PI3K/Akt signalling pathway.

BACKGROUND: Diabetic skin ulcers, a significant global healthcare burden, are mainly caused by the inhibition of cell proliferation and impaired angiogenesis. XB130 is an adaptor protein that regulates cell proliferation and migration. However, the role of XB130 in the development of diabetic skin ulcers remains unclear. AIM: To investigate whether XB130 can regulate the inhibition of proliferation and vascular damage induced by high glucose. Additionally, we aim to determine whether XB130 is involved in the healing process of diabetic skin ulcers, along with its molecular mechanisms. METHODS: We conducted RNA-sequencing analysis to identify the key genes involved in diabetic skin ulcers. We investigated the effects of XB130 on wound healing using histological analyses. In addition, we used reverse transcription-quantitative polymerase chain reaction, Western blot, terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling staining, immunofluorescence, wound healing, and tubule formation experiments to investigate their effects on cellular processes in human umbilical vein endothelial cells (HUVECs) stimulated with high glucose. Finally, we performed functional analysis to elucidate the molecular mechanisms underlying diabetic skin ulcers. RESULTS: RNA-sequencing analysis showed that the expression of XB130 was up-regulated in the tissues of diabetic skin ulcers. Knockdown of XB130 promoted the healing of skin wounds in mice, leading to an accelerated wound healing process and shortened wound healing time. At the cellular level, knockdown of XB130 alleviated high glucose-induced inhibition of cell proliferation and angiogenic impairment in HUVECs. Inhibition of the PI3K/Akt pathway removed the proliferative effects and endothelial protection mediated by XB130. CONCLUSION: The findings of this study indicated that the expression of XB130 is up-regulated in high glucose-stimulated diabetic skin ulcers and HUVECs. Knockdown of XB130 promotes cell proliferation and angiogenesis via the PI3K/Akt signalling pathway, which accelerates the healing of diabetic skin ulcers.

Efficacy of erzhu jiedu recipe on hepatitis B cirrhosis with hyperalphafetoproteinemia: A randomized, double-blind, placebo-controlled clinical trial.

BACKGROUND: Hepatitis B cirrhosis with hyperalphafetoproteinemia is the intermediate stage of liver cirrhosis progressing to hepatocellular carcinoma (HCC), there is no effective way to treat precancerous lesions of liver in modern medicine. In recent decades, clinical and experimental evidence shows that Chinese medicine (CM) has a certain beneficial effect on Hepatitis B Cirrhosis. Therefore, this trial aims to evaluate the efficacy and safety of a CM erzhu jiedu recipe (EZJDR) for the treatment of Hepatitis B Cirrhosis with Hyperalphafetoproteinemia. METHODS: We designed a randomized, double blind, placebo-controlled clinical trial. A total of 72 patients of Hepatitis B Cirrhosis with hyperalphafetoproteinemia were randomized in 2 parallel groups. Patients in the control group received placebo granules similar to the EZJDR. In the EZJDR group, patients received EZJDR twice a day, after meals, for 48 weeks. The primary efficacy measures were changes in serum alpha-fetoprotein (AFP) and alpha-fetoprotein alloplasm (AFP-L3); The secondary indicators of efficacy are changes in liver function indicators, HBV-DNA level; Liver stiffness measurement (LSM); Hepatic portal vein diameter; T lymphocyte subgroup indexes during treatment. All data will be recorded in case report forms and analyzed by Statistical Analysis System software. Adverse events will also be evaluated. RESULTS: The results showed that EZJDR can significantly inhibit the levels of AFP and AFP-L3 in patients with hepatitis B cirrhosis and hyperalphafetoproteinemia and have good security. ETHICS AND DISSEMINATION: The study protocol was approved by the Medical Ethics Committee of Shuguang Hospital, affiliated with University of Traditional Chinese Medicine, Shanghai (NO.2018-579-08-01). TRIAL REGISTRATION: This trial was registered on Chinese Clinical Trial Center (NO.ChiCTR1800017165).

Spin crossover in mononuclear Fe(II) complexes based on a tetradentate ligand.

Three isostructural complexes with the formula [Fe(L5Me)(NCE)2]: L5Me = N,N'-bis(5-methyl-2-pyridylmethyl)ethane-1,2-diamine and E = S (1-S), E = Se (1-Se), E = BH3 (1-BH 3 ) have been synthesized and characterized by single-crystal x-ray diffraction, magnetic susceptibility and DSC studies. All the three derivatives are spin crossover (SCO) active, showing complete one-step spin conversion. The SCO midpoint temperatures (T 1/2) are 193 K for 1-S, 226 K for 1-Se, and 330 K for 1-BH 3 , which are among the highest values for the homologous Fe(II)-NCE complexes with comparable tetradentate ligands. The almost linear Fe-N ≡ C(E) angles are consistent with the strong ligand field (LF) strength imposed by these NCE- co-ligands. Strong hydrogen-like bonding N-H…E was observed to connect the molecules into 2D supramolecular sheets parallel to the bc plane. However, such supramolecular interaction is not sufficient enough to transmit strong cooperativity. A discussion on the factors governing the LF strength and the cooperativity has been made, based on the comparison of analogous complexes and also based on UV-vis spectroscopy studies of the Ni(II) complexes.

Multiresponsive Donor-Acceptor Stenhouse Adduct: Opportunities Arise from a Diamine Donor.

A new donor-acceptor Stenhouse adduct based on a N,N,N'-trimethylethylenediamine donor has been reported. An unprecedented isomer has been isolated, and rich conversions between three isomers have been achieved upon visible-light irradiation or base/acid stimuli. The drastic color change associated with structural conversion has been utilized to selectively sense volatile primary amines as well as high-charged hard Lewis acids (Sc3+, Ti4+, Cr3+, and Al3+).